Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Hospital Universitario Son Espases
Palma, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (25)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Annals of Hematology
-
Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study
Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849
-
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica, Vol. 109, Núm. 6, pp. 1909-1917
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts
JAMA Oncology, Vol. 8, Núm. 3
-
Update on the diagnosis of encephalitis
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 4, pp. 247-257
2021
-
Author Correction: The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome (Scientific Reports, (2017), 7, 1, (12288), 10.1038/s41598-017-11620-3)
Scientific Reports
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
European urology oncology, Vol. 4, Núm. 3, pp. 502-505
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
-
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554
-
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia, Vol. 34, Núm. 2, pp. 589-603
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
-
X chromosome inactivation does not necessarily determine the severity of the phenotype in Rett syndrome patients
Scientific Reports, Vol. 9, Núm. 1
2018
-
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905